ZYBERNO
Stock Report
Updated Aug 31, 2026

Elicio Therapeutics, Inc. (ELTX)

Healthcare • NASDAQ

$2.84

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
6.0/100
POOR BUSINESS
Elicio Therapeutics, Inc. (ELTX) scores 6/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-1,266.4%)
Debt-to-Equity (Solvency Risk):POOR (1.16x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-362.3%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Elicio Therapeutics, Inc. (ELTX) stock report — Zyberno Score 6/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, ELTX generated -$37.16M in Owner Earnings. Capital was deployed as follows: $87.00K invested in capital expenditures. Reinvestment rate: 0.7%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:2.84
Market Cap:$54.65M

Valuation Multiples (2)

P/B Ratio:6.89x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$41.78M

Price Action & Momentum (1)

% of 52-Week High:17.8%
B. Profitability Assessment

Return Metrics (5)

ROA:-139.9%
Reinvestment Rate:0.7%
Fundamental Growth Rate (g):-2.4%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$67.83
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:30.7%
Latest Earnings Filed:2026-08-13
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.77x
Quick Ratio:2.77x
Cash Ratio:2.55x

Leverage Analysis (3)

Debt To Equity Ttm:1.16x
Debt-to-Equity Ratio:1.16x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-23.87x
Times Interest Earned:-23.87

Capital Structure (4)

Working Capital:16,283,000.00
Cash And Cash Equivalents:23,480,000.00
Long Term Debt:$9.54M
Net Debt:-$12.87M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$37.92M

Bottom Line Performance (3)

-$37.84M
Income Before Tax:-$39.57M
Ebitda Ttm:-37,568,000.00

Operating Expenses (5)

Operating Expenses:37,918,000.00
R And D Expense:23,687,000.00
Sga Expense:14,231,000.00
Income Tax Expense:$0.00
Interest Expense:1,580,000.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$31.33M
Current Assets:$25.49M
Ppe Net:2,051,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:23,393,000.00
Current Liabilities:9,202,000.00
Long Term Debt:$9.54M
Short Term Debt:$1.07M

Equity & Capital (3)

Equity:$7.94M
Retained Earnings:-$253.71M
Common Stock:300,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:7,290,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:935,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$38.48M-$38.57M

Investment Activities (2)

Investing Cash Flow:-$16.00K
Capital Expenditures Ttm:87,000.00

Financing Activities (3)

Financing Cash Flow:$8.03M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:835,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:350,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-2.13
-$2.13
Earnings Per Share Ttm:-$1.97

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$1.92

Book Value & Capital (2)

Book Value Per Share:$0.41
Cash Per Share:1.22

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:40.00
Quality Score:15.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$37.16M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.7%
Fundamental Growth Rate (g):-2.4%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-50.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:ELTX
Company Name:Elicio Therapeutics, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:19.24M
Shares Outstanding Basic:19.24M
Shares Outstanding Diluted:19.24M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 03:24:05 UTC
Data Timestamp:2026-08-18T11:46:51.107368
Scroll to Top